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ABSTRACT
Objective Bone morphogenetic protein (BMP)-9, a
member of the transforming growth factor-β family of
cytokines, is constitutively produced in the liver. Systemic
levels act on many organs and tissues including bone
and endothelium, but little is known about its hepatic
functions in health and disease.
Design Levels of BMP-9 and its receptors were
analysed in primary liver cells. Direct effects of BMP-9 on
hepatic stellate cells (HSCs) and hepatocytes were
studied in vitro, and the role of BMP-9 was examined in
acute and chronic liver injury models in mice.
Results Quiescent and activated HSCs were identified
as major BMP-9 producing liver cell type. BMP-9
stimulation of cultured hepatocytes inhibited
proliferation, epithelial to mesenchymal transition and
preserved expression of important metabolic enzymes
such as cytochrome P450. Acute liver injury caused by
partial hepatectomy or single injections of carbon
tetrachloride (CCl4) or lipopolysaccharide (LPS) into mice
resulted in transient downregulation of hepatic BMP-9
mRNA expression. Correspondingly, LPS stimulation led
to downregulation of BMP-9 expression in cultured
HSCs. Application of BMP-9 after partial hepatectomy
significantly enhanced liver damage and disturbed the
proliferative response. Chronic liver damage in BMP-9-
deficient mice or in mice adenovirally overexpressing the
selective BMP-9 antagonist activin receptor-like kinase 1-
Fc resulted in reduced deposition of collagen and
subsequent fibrosis.
Conclusions Constitutive expression of low levels of
BMP-9 stabilises hepatocyte function in the healthy liver.
Upon HSC activation, endogenous BMP-9 levels increase
in vitro and in vivo and high levels of BMP-9 cause
enhanced damage upon acute or chronic injury.
INTRODUCTION
Bone morphogenetic proteins (BMPs) belong to the
transforming growth factor (TGF)-β family of cyto-
kines.1 Currently, about 20 different BMPs have
been identified and are grouped into subfamilies,
according to similarities in their amino acid
Significance of this study
What is already known on this subject?
▸ Bone morphogenetic protein (BMP)-9 is a
member of the transforming growth factor
(TGF)-β family of cytokines, is produced by the
liver and is constantly secreted into the blood
stream.
▸ BMP-9 acts antiproliferative and stabilising on
mature (healthy) vessels but can promote
angiogenesis in different tumours.
▸ BMP-9 induces epithelial to mesenchymal
transition of hepatocellular carcinoma cells and
its protein levels correlate with aggressiveness
of hepatocellular carcinoma in patient samples.
▸ BMP-9 is a high-affinity ligand for the type I
receptor activin receptor-like kinase 1.
What are the new findings?
▸ Hepatic stellate cells (HSCs) are the cellular
source for BMP-9, and HSCs express and
secrete increasing amounts during their
fibrogenic activation.
▸ BMP-9 acts antiproliferative and stabilising on
primary (healthy) hepatocytes including
maintenance of cell polarisation and expression
of metabolic enzymes like cytochrome P450
oxidases.
▸ Low levels of BMP-9 promote hepatic wound
healing and regeneration in mouse models of
acute liver damage.
▸ Absence or inhibition of BMP-9 during chronic
liver damage (repeated injections of CCl4 to
mice) significantly ameliorates fibrogenesis.
How might it impact on clinical practice in
the foreseeable future?
▸ Transient inhibition of BMP-9 by itself or in
combination with existing therapy strategies
could significantly improve the hepatic wound
healing and regeneration capacity upon acute
as well as chronic liver injury.
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sequences. BMPs are secreted glycoproteins involved in a large
array of biological activities including proliferation, differenti-
ation and survival, therefore playing important roles in embry-
ology, tissue regeneration and cancer.1–4 BMPs initiate signalling
from the cell surface by binding to two different types of serine/
threonine kinase receptors (I and II). Formation of the active
ligand–receptor complex induces signal transduction pathways
through phosphorylation of small mothers against decapentaple-
gic (SMAD) proteins, and through SMAD-independent pathways
via mitogen-activated protein kinases (extracellular signal-
regulated kinase, p38 mitogen-activated protein kinases, c-Jun
N-terminal kinase).5 6 BMPs can act in an autocrine or paracrine
manner and the outcome is highly context dependent.7–10
BMP-9 and BMP-10 represent the most recently discovered
members of the BMP family. Whereas most BMPs signal via the
type I receptors activin receptor-like kinase (ALK)2, ALK-3 or
ALK-6, BMP-9 and BMP-10 show highest affinity for
ALK1.11 12 Yet, cells still respond to BMP-9 in the absence of
ALK1 by signalling through ALK2.11 13 BIAcore experiments
have revealed high affinity of BMP-9 to ALK1 and ActRIIB and
lower affinity binding to ALK2 and the other type II receptors
BMPRII and ActRIIA.14 15 Whereas BMP-10 seems to be pri-
marily expressed in the developing heart,16 BMP-9 is preferen-
tially expressed in the liver.17–19 Constitutive low-level
expression results in detectable levels of circulating BMP-9 in
healthy individuals.17 20 Features distinguishing BMP-9 from
other BMPs are among others that it does not bind to the
BMP-co-receptor hemojuvelin or the soluble BMP-antagonist
noggin21 22 and that BMP-9 complexed to its prodomains is bio-
logically active.23 It seems that upon contact with its receptors
BMP-9 always turns into an active conformation, even if it is
still complexed to its prodomains.24 Interestingly, BMP-9 and
BMP-10 can directly bind to ALK1 and ActRIIB with similar
high affinity.14 ALK1-Fc, in which the extracellular domain of
ALK1 is fused to the Fc part of immunoglobulin, serves as an
efficient and specific BMP-9 and BMP-10 ligand trap.25 We have
recently shown that BMP-9 acts protumorigenic on liver cancer
cells.6 26 However, possible functions of BMP-9 on primary
non-transformed hepatocytes (HCs) have not been investigated
in much detail. We therefore aimed at better characterising func-
tions of BMP-9 in healthy and diseased liver. The data demon-
strate that although physiological levels of BMP-9 seem to
stabilise the epithelial phenotype of the parenchyma, high levels
of BMP-9 are counteracting with cellular programmes of wound
healing and/or regeneration; therefore, BMP-9 levels drop tran-
siently during acute damage. Correspondingly, we found that
hepatic wound healing in vivo is more efficient when BMP-9 is
inhibited (by ALK1-Fc) or absent (in BMP-9-deficient animals).
Our data demonstrate that BMP-9 represents an important
factor for liver homeostasis and suggest that transient inhibition
of BMP-9 might be a new option to improve hepatic wound
healing and regeneration processes in patients.
MATERIALS AND METHODS
Adenoviruses
AdLacZ and AdId1 have been used as described previously.27
For construction of AdBMP-9, AdFc and AdALK1-Fc adenoviral
constructs, human coding sequences were recombined by a
clonase reaction in pAD/DEST (Invitrogen), and adenoviruses
were generated according to the manufacturer’s protocol.
Cytokines
Recombinant human BMP-9, BMP-2, BMP-6 and mouse hep-
atocyte growth factor (HGF) were from R&D Systems
(Wiesbaden-Nordenstadt, Germany) and recombinant human
TGF-β1 and platelet derived growth factor (PDGF)-B were from
Peprotech (Rocky Hill, USA).
Antibodies
Western blot: a monoclonal rabbit anti-Smad3 (phospho S423
+S425) antibody (EP823Y) (ab52903) was used to detect
phospho-Smad1/3 (Abcam). A polyclonal rabbit antibody
(detecting phosphorylation at Ser465/467) was used to detect
phospho-Smad2 (Cell Signalling Technology). Rabbit polyclonal
antibody for α smooth muscle actin (αSMA) was from Abcam
(ab7817) and a polyclonal rabbit antibody for glyceraldehyde 3-
phosphate dehydrogenease (GAPDH) and a monoclonal mouse
anti-actin for β-actin were obtained from Santa Cruz.
Immunohistochemistry: A Ki-67 rat anti-mouse antibody was
obtained from Dako. A monoclonal mouse against αSMA
(M0851) was from DAKO, and a monoclonal rabbit anti-cleaved
caspase-3 (Asp175; 5A1E) was from Cell Signalling Technology.
Mice
All experimental animal protocols were performed in accord-
ance with European Community policies, and approved by local
committees. BMP-9-deficient mice were generated as previously
described12 and were maintained on a C57BL/6 background.
Cell isolation and culture
Mouse HCs were isolated from male C57BL/6 mice (8–
13 weeks old) by collagenase perfusion as described.28 Mean
viability of HCs was approximately 95%. Primary HCs were
cultured in three kinds of media: medium 1: Williams’ medium
E supplemented with 10% fetal calf serum (FCS), 2 mM
L-glutamine, 1% penicillin/streptomycin and 100 nM dexa-
methasone. Medium 2: medium 1 without FCS. Medium 3:
Williams’ medium E supplemented only with 2 mM
L-glutamine and 1% penicillin/streptomycin. Freshly isolated
HCs were plated on collagen-coated 3.5 cm plates at a density
of 4×105 cells/dish in medium 1 and incubated in 5% CO2 at
37°C for 4 hours. Medium 1 was replaced with medium 2 for
serum starvation and cell cycle synchronisation. On the second
day, medium 2 was changed to medium 3.
Hepatic stellate cells (HSCs) were isolated from female Balb/c
mice by pronase/collagenase digestion followed by single-step
density gradient centrifugation with Nycodenz (Nyegaard Co.
AS, Oslo, Norway), essentially as previously described for rats.27
Briefly, Balb/c mice (weighing ca. 20 g) were anesthetised and
the abdominal cavity was opened under sterile conditions. The
liver was perfused via the portal vein with Hanks buffered
balanced salt solution without Ca2+ and Mg2+. After complete
perfusion, the liver was transferred to a funnel and perfused
with pronase for 4 min, followed by perfusion with collagenase
for 7 min. The liver was then dissociated and the cell suspension
was submitted to density gradient centrifugation with Nycodenz
and washed several times. Cells were resuspended with
Dulbecco’s modified Eagle’s medium (DMEM)+10% FCS. The
mean purity as determined by ultra violet (UV) autofluorescence
was ≥95%. The cells were then cultured in DMEM, supplemen-
ted with 4 mM L-glutamine, 10% FCS and penicillin (100 IU/
mL)/streptomycin (100 mg/mL). The first change of medium was
performed 1–2 hours after seeding to remove any non-adherent
cells and debris. For stimulation experiments with HSCs, the
concentration of FCS was reduced to 0.5% overnight.
LX-2 is a human HSC line, which was cultured in DMEM
supplemented with 2% FCS, 4 mM L-glutamine and penicillin
(100 IU/mL)/streptomycin (100 mg/mL).
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Scratch assay (LX-2)
LX-2 cells were cultured in 12-well plates until confluency to
determine their wound-closure capacity. The cells were cultured
in medium without FCS overnight. Using a pipet tip, the mono-
layer was scratched carefully, followed by stimulation with
recombinant BMP-9 (at concentrations of 5, 10 and 50 ng/mL).
Images were taken immediately (t=0 hour) and after 24 hours
(seven images per scratch). The remaining diameter of the
untreated condition was set as 1 and treatment conditions were
expressed as ‘fold of untreated’.
Simultaneous isolation of four liver cell types from mouse
liver
After isolation of primary HCs and HSCs (protocols as
described above) from male C57B/6 mice, the remaining cell
fraction was further processed for isolation of liver sinusoidal
endothelial cells (LSECs) and Kupffer cells (KCs) using magnetic
microbeads from Miltenyi (CD146 microbeads for LSEC and
CD11b for KC) as described earlier.29
Human primary HSC isolation and migration assay
Primary human HSCs were isolated and cultured as described.30
In vitro activation of HSCs was achieved by cell culture on
uncoated tissue culture dishes.
Migratory activity of HSCs was quantified using Cultrex 96
Well Cell Migration assay (Trevigen, Gaithersburg, USA) as
described.31 Briefly, HSCs were stimulated or not with BMP-9
for 24 hours. Subsequently, cells were trypsinised and seeded in
DMEM without FCS into the upper compartment of the pro-
vided 96-well micropore plate (10×103 cells/well). The lower
compartment was filled with DMEM supplemented with 10%
FCS to assess directed migration. After incubation at 37°C for
5 hours, cell migration was quantified by fluorimetry with an
EMax Microplate Reader (MWG Biotech, Ebersberg, Germany).
Immunoblot analyses
Total cell protein was harvested on ice with radioimmunopreci-
pitation assay lysis buffer (1×Tris-buffer, 1% Nonidet P40,
0.5% sodium deoxycholate and 0.1% sodium dodecylsulfate) in
the presence of freshly added protease and phosphatase inhibi-
tors (Roche, Mannheim, Germany). Protein concentration was
measured with a Bio-Rad protein assay (Biorad, München,
Germany). Proteins were separated by 4%–12% sodium dodecyl
sulfate/polyacrylamide gel electrophoresis (NuPAGE, Invitrogen)
and transferred to nitrocellulose membranes (Pierce, Rockford,
Illinois, USA). Incubation with the primary antibodies occurred
at 4°C overnight. Horseradish peroxidase-linked secondary anti-
bodies (Santa Cruz, Heidelberg, Germany) were used. The
membranes were developed with Supersignal Ultra (Pierce,
Hamburg, Germany), and chemiluminescence was detected
digitally with a Fujifilm LAS 1000 image detection system.
HC proliferation measurements
Since primary HCs in monolayer culture display only very low
basal proliferative activity, a more sensitive assay to detect
changes in cellular DNA content was performed as described by
Huard et al.32 Briefly, freshly isolated HCs were plated on
collagen-coated 3.5 cm plates at a density of 1.25×105 cells/
dish as described above. On the second day, medium 2 was
changed to medium 3 and the cells were stimulated with HGF
(40 ng/mL), BMP-9 (5–50 ng/mL) or a combination of both for
48 hours. In each experiment, cells derived from a single animal
were used, and treatments were performed in triplicates. Cells
were washed twice with phosphate buffered saline (PBS) and
were frozen at −20°C. To assay DNA content, plates were incu-
bated with 2 mL/well of Sybr Green I working solution (Sybr
Green I 10 000× (Invitrogen, Darmstadt, Germany), diluted
1:2500 in PBS, supplemented with 0.1% (v/v) Triton×100 for
1 hour in the dark. Fluorescence intensity was measured using
an Infinite F200 Pro plate reader (Tecan, Männedorf,
Switzerland) with λexcitation=485 nm and λemission=535 nm.
Four experiments were performed for statistical analysis, and
individual datasets were scaled to the mean of the respective
experiment.
HSC proliferation experiments
Human HSCs (between passage 3 and 5 isolated from four dif-
ferent donors) or LX-2 cells were cultured with or without
BMP-9 (5 ng/mL) for 72 hours, then the cells were dislodged by
trypsin and were counted.
Determination of RNA expression
Total RNA was isolated from cells or tissue and equal amounts
were reverse transcribed into cDNA. High-throughput quantita-
tive real-time PCR (RT-PCR) analysis: total RNA was isolated
from the tissue using RNeasy Mini Kit including on column
genomic DNA digestion with RNase-free DNase Set (Qiagen,
Hilden, Germany) and from cultured cells using high pure RNA
isolation kits from Roche (Mannheim, Germany). RNA was
reverse transcribed to cDNA using avian myeloblastosis virus
reverse transcriptase (Roche). For quantitative RT-PCR, we used
either the Fluidigm’s Biomark high-throughput quantitative (q)
PCR chip platform (Fluidigm, San Francisco, California, USA)
with predesigned gene expression assays from Applied
Biosystems according to the manufacturer’s instructions33 34 or
regular Sybr Green-based RT-PCR was performed (40 PCR
cycles on an ABI Prism 7900HT System). Primers used for
RT-PCR are given in tables 1 and 2. mRNA expression levels
were normalised to suitable housekeeping genes as indicated in
the figure legends.
Sirius red staining and quantification
Sirius red staining was performed for 1 hour (0.1 g Sirius red/
100 mL picric acid; Sigma-Aldrich) as previously described.35
Samples were imaged using an Aperio slide scanner followed by
whole slide image analysis with Aperio ImageScope. For quanti-
fication of positive areas, the Positive Pixel Count V.9.1 algo-
rithm was used (pixel area/mm2/−2.44827×10−7). Three
biological replicas per condition were used to quantify the Sirius
red-positive area. Data are displayed as number of pixels in posi-
tive area versus number of pixels in total area (=positivity).
BMP-9 ELISA
An ELISA for mouse BMP-9 was developed. Nunc maxisorp
plates (Nunc, Denmark) were coated with mouse anti-human
BMP-9 antibodies (1 μg/mL in PBS, R&D Systems, Abington,
UK) O/N at room temperature (RT). Between all steps, plates
were washed with PBS containing 0.05% Tween-20 (Merck).
Plates were blocked with 5% Tween-20, 0.05% sodium azide in
PBS for 1 hour, followed by incubation with plasma samples
(50 μL diluted with 1% bovine serum albumin (BSA) (PAA,
Germany)/PBS) or a standard (recombinant mouse BMP-9,
R&D Systems) for 2 hours at RT. Detection was performed
with biotinylated goat anti-human BMP-9 antibodies (0.2 μg/mL
in 1% BSA/PBS 2 hours, RT), streptavidin-horse radish peroxid-
ase and a substrate reagent pack (all R&D Systems) as described
previously.36 37
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CCl4 animal experiments
Male Balb/c mice (five animals per group) weighing 20–25 g
and 8 weeks old were used for the CCl4 time-course experi-
ments. Liver injury was induced by intraperitoneal injection
of 1.6 g/kg body weight of CCl4 (CCl4 was mixed 1:8 with
mineral oil). Male C57BL/6 mice were used for chronic
liver injury, which received three intraperitoneal injections
of CCl4 per week for 4 weeks. At day 7 (after 1 week and
three CCl4 injections), animals received an intravenous
injection of 109 viral particles (AdFc or AdALK1-Fc) in
50 mL saline. Animals were sacrificed after 4 weeks and liver
samples were snap frozen in liquid nitrogen or fixed in 4%
buffered formalin for histology. The same protocol was per-
formed for experiments with wild-type versus BMP-9 knock
out (KO) mice, but with only two injections per week for a
period of 8 weeks in total.
Acute injury animal experiments (LPS and CCl4)
Male C57BL/6 mice were used for acute liver injury studies.
Mice received one intraperitoneal injection of either lipopoly-
saccharide (LPS) (1 mg/g body weight), CCl4 (1.6 g/kg body
weight) or PBS (control). In addition, one group of animals
received recombinant BMP-9 (100 ng per mouse) alone every
24 hours or in combination with the LPS/CCl4 injections. Mice
were sacrificed at the times indicated in the figures, and blood
and livers were collected.
Partial hepatectomy
Two-third partial hepatectomy (PH) experiments with mice
were carried out as described.38 Half of the mice additionally
received recombinant BMP-9 every 24 hours as described above.
Mice were sacrificed at the times indicated in the figures, and
blood and livers were collected.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue sections were dewaxed
and rehydrated through a graded ethanol series and incubated at
60°C for 60 min. Antigen unmasking was performed using a
citrate buffer (0.01 M sodium citrate pH 6) in a water bath at
95°C for 20 min followed by cooling in distilled water. Tissues
were covered with some drops of ‘Dual Endogenous Enzyme
Block’ in a humid atmosphere for 15 min. After sections were
washed with PBS, they were incubated with the diluted first
Table 1 Sequences of the mouse primers used for real-time PCR (always in 50≥30 orientation)
Target gene Forward sequence Reverse sequence






























ALK, activin receptor-like kinase; αSMA, α smooth muscle actin; BMP, bone morphogenetic protein; CTGF, connective tissue growth factor; Pcna, proliferation cell nuclear antigen;
Smad, small mothers against decapentaplegic; TGF, transforming growth factor; VEGF, vascular endothelial growth factor.
Table 2 Sequences of the human primers used for real-time PCR
(always in 50≥30 orientation)
Target gene Forward sequence Reverse sequence
β2 Microglobulin GACTTGTCTTTCAGCAAGGA ACAAAGTCACATGGTTCACA
Col1a1 GTGCGATGACGTGATCTGTGA CGGTGGTTTCTTGGTCGGT
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antibody at 4°C overnight. The corresponding secondary anti-
bodies were added for 1 hour at RT. Sections were covered with
200 mL 3,30-diaminobenzidine (DAB) substrate. Colour develop-
ment was monitored under the microscope and the reaction was
stopped by immersing the sections in distilled water for 5 min.
Sections were counterstained in Mayershaemalaun solution for
several seconds and rinsed with water, followed by dehydration
through ascending ethanol. Clearing was performed in xylene,
and sections were mounted with malin oil.
Patient samples
Frozen human liver fibrosis samples were provided by the tissue
bank of the National Center for Tumor Diseases (NCT,
Heidelberg, Germany) in accordance with the regulations of the
tissue bank and the approval of the ethics committee of
Heidelberg University (Ethikvotes # 206/207, year: 2005).
Immunohistochemical stainings on human cryosections
Immunohistochemical stains were performed on an automated
immunostainer with an iVIEW DAB detection kit (Ventana/
Roche, Tucson, USA) using primary Bmp-9 antibody (1:500,
Bio rad) and counterstained with haematoxylin. All slides were
evaluated by at least one board certificated surgical pathologist.
Statistics
Two-sided, unpaired Student’s t-test was used to identify signifi-
cant differences between groups. Classification of significances
was determined as follows: p<0.05=*; p<0.01=**;
p<0.001=***.
RESULTS
HSCs are source and target of BMP-9 in mouse liver
To molecularly dissect hepatic functions of BMP-9, we first ana-
lysed which cell type of the healthy liver expresses the highest
levels of BMP-9 mRNA. Towards this end, we isolated four dif-
ferent liver cell types (HC, HSC, LSEC and KC) simultaneously
from livers of healthy male mice and directly lysed the cells for
RNA purification. Successful enrichment of individual cell types
was verified by analyses of expression levels of specific cell-type
markers (see online supplementary figure S1). HSCs express
highest levels of BMP-9 mRNA (figure 1A). Analysis of BMP-9
receptor expression revealed a heterogeneous expression pattern
with each cell type expressing at least one of the two high-
affinity receptors: ALK1 or ActRIIB. HSCs and LSECs also
expressed similar levels of ALK2, an alternative type I receptor
for BMP-9 with lower affinity, as well as endoglin, a co-receptor
for BMP-9-signalling (see online supplementary figure S2).
Cultured HSCs are known to spontaneously activate and dif-
ferentiate into myofibroblasts.39 We therefore analysed BMP-9
expression dynamics (RNA and secreted protein) during in vitro
activation. Both, mRNA expression and protein secretion of
BMP-9 significantly increased in culture and maintained at ele-
vated levels at least for 1 week (figure 1B, C). Furthermore,
BMP-9 directly enhanced the wound-closure potential (deter-
mined by scratch assay) of the human HSC cell line, LX-2
(figure 1D) and stimulated migration of cultured primary
human HSCs (figure 1E). While BMP-9 did enhance prolifer-
ation of cultured HSCs (LX-2 as well as primary human HSCs;
figure 1F, G), it had no modulatory effect on the expression of
markers associated with the in vitro activation process (figure 1
H, I). Stimulation with TGF-β was used as positive control in
these experiments and led to statistically significant changes as
expected (upregulation of Col1a1, fibronectin and Pdgfb and
downregulation of Pparγ). Consistently, culturing primary
mouse HSCs in the presence of BMP-9 neutralising ALK1-Fc
did not change expression of activation markers, indicating that
the cells activate in vitro even without BMP-9 (figure 1H).
BMP-9 stabilises epithelial properties of primary HCs
BMP-9 has been described as a vascular quiescence factor, stabi-
lising the differentiated phenotype of mature endothelial cells.20
Primary HCs and hepatoma cell lines are responsive to
BMP-9.6 18 26 Primary mouse HCs stimulated in culture with
recombinant BMP-9 displayed upregulation of typical
BMP-target genes including Id1, hepcidin (hamp1) or Smad6
(figure 2A). BMP-9 inhibited baseline as well as HGF-induced
HC proliferation (figure 2B). Primary HCs cultured as mono-
layer rapidly lose their epithelial phenotype and acquire mesen-
chymal properties (epithelial to mesenchymal transition
(EMT)40 41). As shown in figure 2C, BMP-9 dose dependently
reversed the culture-provoked upregulation of mesenchymal
markers like collagen I and fibronectin, as well as downregula-
tion of the epithelial marker E-cadherin. In addition,
TGF-β-mediated induction of the EMT transcription factor
Snail42 was inhibited by BMP-9 (see online supplementary
figure S3). Similarly, BMP-9 enhanced RNA expression of 23
out of 37 tested enzymes and other proteins involved in meta-
bolic activities of HCs (figure 2D). To further investigate the
role of BMP-9 in stabilising the HCs’ epithelial phenotype, we
isolated primary HCs from the livers of BMP-9 KO mice and
measured the expression levels of three mesenchymal and three
epithelial marker genes. The result shown in figure 2E demon-
strates that without BMP-9 HCs express significantly higher
levels of mesenchymal and lower levels of epithelial markers,
compared with cells isolated from wild-type livers.
BMP-9 expression is transiently reduced under conditions
of acute liver damage
To assess whether BMP-9 levels might change under conditions
of liver damage in vivo, hepatic BMP-9 mRNA expression levels
were determined in three different animal models of acute liver
damage: single injections of CCl4 or LPS and liver regeneration
upon removal of 2/3 of the liver (PH). There was a transient
downregulation of BMP-9 expression shortly after onset of
damage in all three models (figure 3A–C). At later time points,
BMP-9 expression was elevated on LPS or CCl4 injection
(figure 3A–C). Furthermore, LPS treatment downregulated
BMP-9 expression in cultured HSCs (figure 3D).
Corresponding to the observed antiproliferative effects of
BMP-9 on HCs (figure 2B), the drop of BMP-9 expression after
PH (figure 3C) as well as after one injection of CCl4 (figure 3A)
coincided with previously described time points of enhanced
HC proliferation, which peaks 24–48 hours after PH38 and 48–
72 hours after CCl4 injection.43 In line with this, expression
levels of the proliferation cell nuclear antigen were rapidly upre-
gulated after a single injection of LPS and thereby opposed the
BMP-9 levels at early time points (8 hours; figure 3B). We next
examined the outcome of counterbalancing the downregulation
of endogenous BMP-9 expression by exogenous BMP-9 at early
time points after induction of damage. Indeed, injection of
recombinant BMP-9 resulted in a significant enhancement of
liver damage as reflected by increased circulating levels of lactate
dehydrogenase (LDH), aspartate aminotransferase (AST) and
alanine transaminase (ALT) on day 2 after PH (figure 4A).
Moreover, overall proliferation was significantly reduced in
BMP-9-treated animals (figure 4B), in spite of enhanced mRNA
expression of the proproliferative cytokines CTGF and VEGF
(figure 4C).
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Figure 1 Hepatic stellate cells (HSCs) are source and target of bone morphogenetic protein (BMP)-9. (A) Four different liver cells types
(hepatocytes (HCs), HSCs, liver sinusoidal endothelial cells (LSECs) and Kupffer cells (KCs)) were simultaneously isolated from healthy mouse livers,
directly lysed and total RNA was purified. BMP-9 expression levels were determined by real-time PCR. Data are expressed as average values±SD
(derived from n=8 isolations). Because no housekeeping gene was equally expressed in all cell types, the ΔCt for BMP-9 versus the average Ct of all
four samples per experiment was calculated and expressed as % of total expression. (B) BMP-9 mRNA levels during in vitro activation (up to 6 days
of culture) of primary mouse HSCs. Significant changes are indicated in relation to the 1-day time point. Ct values for BMP-9 were normalised to the
housekeeping gene Ppia. (C) BMP-9 secretion from in vitro activated HSCs, measured by ELISA using samples from the conditioned medium of
cultured primary mouse HSCs. Significant changes are indicated in relation to the 1-day time point. (D) Scratch assay, performed with LX-2 cells
(human HSC cell line). (E) Migration assay, performed with primary human HSCs (average±SD of n=7 cell isolations). LX-2 (F) or primary human
HSCs (passage 3–5) (G) were cultured with or without BMP-9 (5 ng/mL) for 72 hours and cells were counted. As positive internal control, LX-2 cells
were stimulated with platelet derived growth factor (PDGF)-BB (20 ng/mL) as indicated. The graphs show the average cell numbers (for LX-2 (F): n=3
experiments; for (G) primary cells from four different donors were used) ±SD. (H) Expression of HSC activation markers (Col1a1, fibronectin (fn),
PDGF-B (pdgfb), Pparγ (pparg) and αSMA) was determined by real-time PCR in primary mouse HSCs (average of n=3 cell isolations±SD) 24 hours
after stimulation as indicated. (I) Primary human HSCs (passage 3–5, derived from three different donors) were stimulated with BMP-9 (5 ng/mL) for
72 hours and expression of Col1a1 was determined by real-time PCR. Statistical differences were classified as follows: *p<0.05; **p<0.001;
***p<0.0001. ALK, activin-like kinase; Ppia, peptidylprolyl isomerase A; αSMA, α smooth muscle actin; TGF, transforming growth factor; ut, untreated.
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Figure 2 Effects of bone morphogenetic protein (BMP)-9 on primary mouse hepatocytes in vitro. (A) Induction of mRNA expression of classical
BMP-target genes (Id1, hepcidin and Smad6) was analysed by real-time PCR. Data are expressed as average values±SD. Ct values for the target genes
were normalised to the housekeeping gene β-actin. Significant changes are indicated in relation to the corresponding time point of the untreated (ut)
samples. (B) Using a Sybr Green I-based assay DNA levels in hepatocytes were determined within 48 hours of culture with the indicated stimulations.
Addition of hepatocyte growth factor (HGF) (40 ng/mL) potently triggered DNA synthesis which was attenuated by co-treatment with BMP-9 (5 and
50 ng/mL). (C) Real-time PCR results showing that with prolonged culture of primary hepatocytes, the cells continuously induce expression of
mesenchymal proteins like collagen 1a1 and fibronectin and reduce expression of the epithelial cadherin (E-Cadherin). In the presence of BMP-9, these
regulations were significantly inhibited. Data are expressed as in panel A. (D) Hepatocytes were cultured in the presence or absence of BMP-9 (5 ng/mL)
for either 24 hours (0≥24 hours), 48 hours (0≥48 hours) or first for 24 hours without and then another 24 hours with BMP-9 (24 hours≥48 hours) and
the mRNA expression levels of 37 proteins involved in drug metabolisation processes were investigated by real-time PCR using Fluidigm analyses. The
heatmap illustrates changes of ADME gene expression signatures in hepatocytes upon BMP-9 treatment and shows that approximately 60% of analysed
genes are higher expressed (threshold 1.5-fold, marked with big asterisk) at least at one time span upon BMP-9 stimulation. (E) Expression of
mesenchymal and epithelial marker genes were analysed by real-time PCR in freshly isolated hepatocytes from wild-type versus BMP-9 KO mice.
Statistical differences were classified as follows: *p<0.05; **p<0.001; ***p<0.0001.
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Lack of BMP-9 in vivo ameliorates liver fibrosis upon
repeated injections of CCl4
To analyse long-term BMP-9 effects, we interfered with
BMP-9 signalling, using an adenovirus expressing a soluble
form of the BMP-9 type I receptor, ALK1 (AdALK1-Fc). In
contrast to BMPs, TGF-β first binds to its type II receptor
(TβRII). TGF-β/TβRII complex associates only thereafter with
a type I receptor. The direct affinity of TGF-β alone to any
type I receptor (ALK1 or ALK5) is low (reviewed in44).
Therefore, ALK1-Fc protein selectively targets BMP-9 and
does not inhibit TGF-β signalling. To verify this and to also
confirm that ALK1-Fc did not neutralise the effects of other
BMPs, we performed western blot analyses for phosphorylated
SMAD proteins (see online supplementary figure S4A, B).
SMAD-1 phosphorylation by BMP-9 was efficiently inhibited
by ALK1-Fc (see online supplementary figure S4C). Moreover,
chronic CCl4-treated mice that received AdALK1-Fc had
strongly reduced levels of circulating BMP-9 compared with
those receiving CCl4 and a control virus AdFc (see online
supplementary figure S4C).
Using this approach, we next examined the consequences of
BMP-9 neutralisation under conditions of chronic liver damage.
Liver fibrosis in mice was experimentally induced by repeated
injections of CCl4. One group of animals served as solvent
control (CCl4+saline), a second group received a control virus
(CCl4+AdFc) and BMP-9 was neutralised in the third group by
injecting an adenovirus expressing ALK1-Fc
(CCl4+AdALK1-Fc). Animals receiving repeated injections of
CCl4 for 4 weeks developed fibrosis, which was significantly
reduced by AdALK1-Fc (figure 5A, B). When analysing RNA
levels for collagen in the livers of these animals, we found a cor-
respondingly reduced expression in the AdALK1-Fc group
(figure 5C). Expression of the BMP target gene Id1 was also
strongly reduced, implying that BMP-9 induced Id1 expression
during fibrogenesis, which was in line with our previous obser-
vation that HSCs upregulate Id1 expression during activation.27
The data further show that BMP-9 expression ( just like that of
TGF-β) increases with fibrosis development. While this rise in
BMP-9 levels was strongly prevented by AdALK1-Fc, TGF-β
levels remained elevated (figure 5C). Immunostaining for
cleaved caspase-3 showed significantly reduced overall apoptosis
rates in AdALK1-Fc-treated animals (figure 5D). Robustness of
these results was confirmed in mice with genetic depletion of
BMP-9 in the CCl4-induced liver fibrosis model, where lack of
BMP-9 signalling in BMP-9 knockout mice led to a milder
development of fibrosis, as compared with controls (figure 6A).
As in the AdALK1-Fc setup, upregulation of αSMA protein was
significantly reduced in the CCl4-treated BMP-9 KO mice com-
pared with the wild types (figure 6B, C). Also here, BMP-9
mRNA expression was induced by CCl4 in the wild types and
TGF-β mRNA expression was still enhanced even in the absence
of BMP-9 and despite a decreased fibrosis (figure 6D). In accord-
ance with the Sirius red staining results shown in figure 6A,
induction of Col1a1 was significantly reduced in the KO mice
(figure 6D). Changes in fibronectin and desmin expression were
not significantly different between CCl4-treated wild types and
BMP-9 KO mice but in both cases basal expression was enhanced
in the BMP-9 KO mice (see online supplementary figure S5B). In
contrast to the AdALK1-Fc approach, upregulation of the
BMP-target gene Id1 still also occurred in the absence of BMP-9
(figure 6D), which might be the result of adaptations in the BMP
signalling network which had time to develop in the KO mice
but not in the AdALK1-Fc-treated animals. Hepcidin, another
BMP-target gene, was not changed by CCl4, but was generally
Figure 3 Transient downregulation of BMP-9 expression on acute
liver damage. To cause conditions of acute liver damage followed by
wound-healing/regeneration processes, mice were either injected once
(intraperitoneally) with CCl4 (A) or with lipopolysaccharide (LPS) (B) or
underwent partial hepatectomy (PH) (C). At the indicated time points,
the animals were sacrificed, the livers were preserved and total RNA
was isolated. Levels of BMP-9 or PCNA were determined by real-time
PCR and are plotted as average of normalised values±SD. For the
zero-hour time points, livers of age matched, untreated animals were
used. The arrows indicate the time points of lowest BMP-9 expression
in each model. (D) Primary mouse hepatic stellate cells (HSCs) were
cultured for 8 days (ut). LPS (100 ng/mL) was either added for 24 hours
(from day 7 to day 8; ‘acute’) or constantly (from day 1 to day 8;
‘chronic’) and total RNA was isolated. Levels of BMP-9 mRNA were
determined by real-time PCR and are expressed as average of
normalised values±SD. β2M,β2 microglobulin (housekeeping gene);
BMP-9, bone morphogenetic protein 9; Ppia, peptidylprolyl isomerase
A (housekeeping gene); PCNA, proliferation cell nuclear antigen; ut,
untreated.
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almost absent in the BMP-9 KO mice (see online supplementary
figure S5B), indicating that without BMP-9 hepcidin seems to be
generally low expressed. Smad6 expression was unchanged in
KO mice compared with wild types and although there was a
tendency of reduced expression of the epithelial marker
E-Cadherin in the KO mice, in whole liver lysates this differ-
ence was not statistically relevant (see online supplementary
figure S5B). As expected, the liver damage markers AST and
ALT showed a clear tendency of reduction in the serum of the
CCl4-treated KO mice compared with wild type (see online
supplementary figure S5B) further evidencing a decreased liver
damage in the BMP-9 KO mice. Overall proliferation in the
CCl4-treated KO mice as determined by immunostaining
against Ki67 was significantly reduced compared with the wild-
type animals (figure 6E).
Thus, two different experimental approaches both supported
the conclusion that high levels of BMP-9 facilitate CCl4 induced
liver fibrogenesis in mice.
Figure 4 High levels of bone
morphogenetic protein (BMP)-9 lead to
enhanced tissue damage reduced
proliferation and enhanced CTGF and
VEGF expression 2 days after partial
hepatectomy (PH). PH (n=6–8 animals
per group) was performed and
recombinant BMP-9 (4 ng per g body
weight) or equal amounts of
phosphate buffered saline (PBS) were
injected intraperitoneally every
24 hours. (A) After 2 days, the animals
were sacrificed, blood was preserved
and levels of LDH, AST and ALT were
determined. All differences between
the PBS and BMP-9 groups were
statistically significant (p<0.05). (B)
Proliferation was determined by
immunostaining for Mki67. One
representative picture per group is
shown. The graph shows the average
amount of positive staining per surface
area (as calculated from five randomly
chosen areas per mouse using ImageJ
software). (C) Levels of VEGF and
CTGF mRNA in total liver lysates (day
2 after PH) were determined by
real-time PCR and are expressed as
average of normalised values±SD.
CTGF, connective tissue growth factor;
Ppia, peptidylprolyl isomerase A
(housekeeping gene); VEGF, vascular
endothelial growth factor.
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Potential role of BMP-9 in human liver fibrosis
To address the question if our results with mice are transferable
to the human situation, we performed immunostaining against
BMP-9 in cryosections from normal and fibrotic human livers
(figure 7). We found positive staining in normal liver in stellate-
shaped, non-parenchymal cells and in the walls of larger blood
Figure 5 Sequestration of bone morphogenetic protein (BMP)-9 reduces fibrogenesis in vivo. An activin-like kinase 1 (ALK1)-Fc overexpressing
adenovirus (AdALK1-Fc) was injected intraperitoneally (once) to mice which additionally received three injections of CCl4 per week for a total of
4 weeks. An adenovirus equal to AdALK1-Fc but lacking the receptor sequence (AdFc) was used as control. (A) CCl4 led to a massive deposition of
fibrous matrix within the liver as determined by Sirius red staining which was significantly reduced by co-application of AdALK1-Fc (the graph shows
the quantification of the staining intensities). (B) Immunohistochemical stainings for α smooth muscle actin (αSMA) (representative pictures). (C)
Real-time PCR analyses using total liver lysates showing that CCl4-mediated fibrogenesis was accompanied by increased expressions of BMP-9, Id1,
collagen I and TGF-β mRNAs. All three were reduced significantly by AdALK1-Fc. (D) Immunohistochemical stainings for cleaved caspase-3
(reddish-brown colour), representative pictures and quantification of staining intensities of whole section scans from n=5 animals per group (graph).
The arrows point to individual positive cells located along a fibrotic septum. In the AdALK1-Fc group, the amount of cleaved caspase-3 positive
staining was significantly reduced.
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vessels, especially with onset of HSC activation (early fibrogen-
esis). This pattern fits well with the hypothesis that also in
human liver HSCs located at the sinusoids and in the walls of
larger vessels are principally positive for BMP-9 synthesis. Bile
duct epithelium appeared rather negative. In line with this, in
moderate fibrosis positive staining was found in those areas
where activation of HSCs can be expected. In fully established
fibrotic septae, staining seemed to be less intense, though still
present.
When searching publicly available array data with human
liver samples, we found two cohorts which investigated normal
liver samples versus hepatitis-B-virus (HBV)-mediated damage
(see online supplementary figure S6A, B). BMP-9 itself was sig-
nificantly upregulated in the samples from patients with acute
liver failure (GSE38941), but not significantly changed with
increasing fibrosis stages (GSE84044). The co-receptor endoglin
was significantly enhanced in samples of fibrosis stages 2 and 4
(GSE84044), but not in the acute liver failure cohort
(GSE38941). However, expression of the BMP-9 receptor ALK1
was significantly upregulated in both cohorts, indicating that
under conditions of damage the number of ALK1-positive cells
and thereby the sensitivity and responsiveness to BMP-9 stimula-
tion increases. Thereby local elevations of BMP-9 might directly
affect the cellular crosstalk, for example, between activated
HSCs and LSECs.
DISCUSSION
Although BMP-9 is constitutively expressed in healthy liver,17 19
knowledge about its physiological functions is still very limited
(for review, see45). Whereas inhibition of BMP-9/ALK1 signal-
ling is already discussed as a potential anti-angiogenic strategy
in cancer46 and clinical application of rhBMP-9 was recently
presented as a potentially promising new approach to promote
fracture healing,47 its possible roles during acute or chronic liver
Figure 6 Bone morphogenetic protein (BMP)-9 knockout mice develop less fibrosis upon CCl4 challenge in vivo. Wild-type or BMP-9 KO mice were
injected intraperitoneally with CCl4 or mineral oil for 8 weeks. (A) In the wild-type animals, CCl4 led to a massive deposition of fibrous matrix within
the liver as determined by Sirius red staining which was significantly reduced in BMP-9 KO mice (the graph shows the quantification of the staining
intensities). (B) Immunohistochemical stainings for α smooth muscle actin (αSMA) (representative pictures and quantification). The photo on the left
shows the result of the negative control (no primary antibody added). (C) Investigation of αSMA protein expression by immunoblot analysis
(representative western blot plus quantitative densitometric analysis of samples from n=5–10 mice per condition). (D) Expression levels of BMP-9,
TGF-β, Collagen I (Col1a1) and Id1 were investigated by real-time PCR in whole liver samples and were normalised to the housekeeping gene Gusb.
Data are expressed relative to untreated samples (assigned an arbitrary value of 1) and are mean±SEM. of at least seven animals. (E)
Immunohistochemical detection of Ki67 in liver sections. For quantification, positive cells from a total of 16 fields of sections from at least four
animals per group were counted and are presented as average±SD.
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damage were only insufficiently investigated up to now. In the
present work, we therefore addressed this point and investigated
BMP-9 expression levels, cellular responses and in vivo conse-
quences of BMP-9 signalling in liver cells in vitro as well as in
diverse mouse models for acute and chronic liver damage.
The results demonstrate that (1) the HSC is the main
BMP-9-producing cell type in the liver, (2) BMP-9 expression
further increases when HSCs become activated leading to
higher levels during fibrogenesis, (3) neutralisation of BMP-9
ameliorates fibrogenesis and (4) BMP-9 stabilises the epithelial
properties of HCs and controls their proliferation in vitro as
well as in vivo at early time points after acute damage.
Profibrogenic action of BMP-9
The finding that the liver is the main organ that produces
BMP-9 (at least under healthy conditions) seems undoubted,17 19
but the exact hepatic cell type secreting BMP-9 was controver-
sially reported. Miller et al19 detected high BMP-9 expression in
rat liver, and specified non-parenchymal cells (HSC, LSEC and
KC) but not HCs as producing cell types. Another study using
human samples confirmed the highest expression of BMP-9 in
liver but when analysing commercially obtained RNA samples
from diverse human liver cell types (bile duct cells, HCs, HSCs
and LSECs), they found highest BMP-9 expression in bile duct
cells followed by HCs and only rather low expression in HSCs
and LSECs.17 Our results confirm the data of Miller et al19
showing highest BMP-9 transcript expression in HSCs (figure 1A).
HCs, in contrast, expressed very low, almost undetectable levels.
Although we did not find evidence for a direct enhancement of
activation in vitro (no significant induction of aSMA, collagen I,
fibronectin or Pdgfb mRNA expression by BMP-9 stimulation
and no reduction of Pparγ; figure 1H, I), these cells obviously
produce BMP-9 under quiescent conditions, which is further
enhanced on fibroblastic activation in vitro (figure 1B, C). This
finding implied that liver fibrogenesis might be accompanied by
enhanced presence of BMP-9 in vivo. Consistently, BMP-9 and
its direct target gene Id1 are strongly upregulated at the tran-
script level in fibrotic livers of mice that received repeated
Figure 6 Continued
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injections of CCl4 (figures 5C and 6D). We further document
enhanced HSC migration and proliferation by BMP-9. Based on
this and the increased BMP-9 secretion from activated HSCs,
locally high levels of BMP-9 at sites of liver damage where fibro-
sis develops can be expected and were indeed observed by
immunostaining of fibrotic human liver samples (figure 7). To
analyse if elevated BMP-9 expression is indeed functionally
related to fibrogenesis under conditions of chronic damage
(repeated injections of CCl4), we used two different approaches:
first, we adenovirally overexpressed a soluble form of the
BMP-9 receptor ALK1 (by AdALK1-Fc), which binds and
thereby neutralises BMP-9 protein. Because neither TGF-β nor
other BMPs (except BMP-10) exert high affinity to ALK1 alone
(in the absence of a type II receptor), ALK1-Fc selectively neu-
tralises BMP-9 (see online supplementary figure S4). In the
second approach, we used BMP-9 KO mice. On repeated injec-
tions of CCl4 for several weeks, all mice developed liver fibrosis.
When BMP-9 was neutralised (by ALK1-Fc) or absent (in the
KO mice), the degree of fibrosis was clearly reduced (figures 5
and 6). These data suggest that in the context of chronic liver
injury, BMP-9 aggravates liver fibrogenesis in vivo. The under-
lying mechanism most likely involves enhanced migration and
proliferation of activated HSCs (figure 1D–G) and at least in the
AdALK1-Fc model also induction of Id1 which we had already
earlier identified as a fibrosis-regulating factor.27 In the KO mice
treated with CCl4, Id1 expression was still significantly upregu-
lated (figure 6D) which could be a result of adaptation processes
that may have occurred in these mice. Since LSECs can directly
control HSC activation48 and the BMP-9 receptor ALK1 was
highly expressed in freshly isolated LSECs (see online
supplementary figure S2), the profibrogenic effects of BMP-9
that we observed might as well be the result of a cellular cross-
talk between HSCs and LSECs. In line with this hypothesis, we
found significantly enhanced ALK1 expression in fibrotic human
samples as derived from publically available array data with
human liver samples (GSE38941 and GSE84044; online
supplementary figure S6A, B) implying that the sensitivity of
liver cells to BMP-9 stimulation should increase with
fibrogenesis.
BMP-9 functions as stabiliser of HC epithelial properties
It is well established that isolated HCs in culture rapidly lose
their epithelial and functional properties and that they spontan-
eously undergo a dedifferentiation process towards a mesenchy-
mal cell type.40 41 This process, which exerts features of an
EMT, is further enhanced in the presence of TGF-β.40 On EMT,
Figure 7 Representative examples of immunohistochemical stainings against bone morphogenetic protein (BMP)-9 in cryosections from (A) normal
and (B) fibrotic human livers. BD, bile duct.
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HCs downregulate expression of many enzymes and genes
needed for proper metabolic functions of the liver. The conclu-
sion from these findings is that only polarised (epithelial) HCs
are capable of efficiently processing xenobiotics or endogenous
substances. On the other hand, under conditions of damage or
on malignant transformation of HCs, EMT enables the cells to
proliferate and to become motile. BMP-9 exerted significant
antiproliferative and anti-EMT activities on primary cultured
mouse HCs in vitro (see figure 2B, C and online supplementary
figure S3). In addition, BMP-9 led to enhanced and preserved
expression of important drug metabolising enzymes, especially
cytochrome P450 oxidases (figure 2D) and BMP-9 KO HCs
expressed significantly less epithelial and more mesenchymal
markers than wild-type cells (figure 2E). These findings imply
that the basal presence of BMP-9 in healthy liver might contrib-
ute to maintain functionality of parenchymal cells. Nevertheless,
since BMP-9 knockout mice are viable and fertile, showing no
overt phenotype,12 these basic hepatic functions of BMP-9 seem
to be largely dispensable or can become compensated by other,
so far not identified factors or mechanisms.
Our observation that BMP-9 acts as an antiproliferative and
stabilising factor on primary HCs fits well to its previously
reported properties as ‘quiescence factor’ for the (healthy) epi-
thelium.20 Nevertheless, we and others also reported
EMT-promoting effects of BMP-9 on hepatocellular carcinoma
cells.6 26 This, together with the finding that BMP-9 neutralising
agents are already in clinical trials as anti-angiogenic strategy
against cancer growth,46 makes us conclude that at least in HCs
and endothelial cells, BMP-9 exerts completely opposite func-
tions in malignant versus non-malignant conditions. How these
opposing functions are mechanistically mediated and controlled
is not known but might be related to diverse expression levels of
the individual receptors and co-factors, or might be brought
about by crosstalk of BMP-9 signalling with other pathways.
On acute liver damage, BMP-9 needs to be transiently
downregulated
We then investigated the hepatic expression levels of BMP-9 in
three different mouse models of acute liver damage/regener-
ation, namely PH and single injections of either LPS or CCl4. In
each of these models, we found a transient reduction of BMP-9
expression levels at early time points (figure 3A–C).
Considering that almost any kind of liver injury goes along
with an increase of gut-derived bacterial toxins such as LPS in
the blood,49–53 it is well conceivable that this effect of acute
liver injury on BMP-9 expression may be due to inhibitory
effects of LPS on HSCs, which represent the major source of
BMP-9 (figure 1A). In line with this assumption, LPS treatment
results in a downregulation of BMP-9 levels in liver tissue in
vivo (figure 3B) and strongly suppresses BMP-9 expression levels
in HSCs (figure 3D) in vitro. Similar to KCs and sinusoidal
endothelial cells, HSCs also express the LPS receptor Toll like
receptor (TLR)-4 and respond to LPS treatment with proinflam-
matory signalling.54 We further found that counteracting such
drop of BMP-9 in vivo 2 days after PH resulted in significantly
enhanced liver damage (figure 4A). In accordance with the
above-described antiproliferative effects of BMP-9 on HCs,
these animals showed a reduced level of Mki67-positive cells
(figure 4B). This was accompanied by significantly upregulated
expressions of the proproliferative cytokines VEGF and CTGF
mRNA (figure 4C), which might be a mechanism of compensa-
tion of the antiproliferative effect of BMP-9.
These data support the concept that rapid reduction of BMP-9
expression (possibly via LPS) after acute damage might be needed
to allow for transient HC proliferation and plasticity, features that
are essential for optimal wound healing. Ongoing studies aim at
further analysing the interplay of BMP-9 with LPS and its possible
role in modulating inflammatory processes in the liver.
Under conditions of chronic damage (repeated injections of
CCl4), absence or neutralisation of BMP-9 reduced fibrogenesis
and in this context overall proliferation was also reduced
(figure 5D) indicating that the antiproliferative effects of BMP-9
on HCs might be rather important during acute damage than
during chronic processes. This hypothesis is supported by our
observation that the rapid reduction in BMP-9 expression in the
three models of acute damage (figure 3A–C) always correlated
with the onset of HC proliferation (for the LPS injection model
this is shown in figure 3B, for CCI4 injection and partial hepa-
tectomy the proliferation time courses have been reported previ-
ously29 43), similar to the results previously published by
Mogler et al29 and Hoehme et al43.
At first sight, it may seem contradictory that BMP-9 on the
one side optimises HC polarisation and functionality, but on the
other side high levels of BMP-9 seem to generally enhance liver
damage. We think that the functions of BMP-9 as a stabiliser of
the parenchyma—although possibly beneficial under healthy
conditions—might become impedimental under conditions of
damage, where actions such as proliferation and plasticity are
essentially needed, at least transiently. In addition, it seems very
probable that BMP-9 may indirectly affect HSC activation and
fibrogenesis by acting on other BMP-9-responsive liver cell
types, like LSEC, which we showed to express even higher
levels of all tested BMP-9 receptors than HSC (see online
supplementary figure S2). For example, capillarisation of LSECs,
a feature associated with liver damage including fibrogenesis,55 56
might be affected by high levels of BMP-9.
In summary, our data show that increasing levels of BMP-9
under conditions of damage pave the way to liver fibrogenesis,
whereas absence or inhibition of BMP-9 supports the road to
wound healing and liver regeneration. If this concept can be
further confirmed in human, neutralisation of BMP-9 could
become an important therapeutic approach to maximise the effi-
ciency of antifibrotic medications of the liver, and possibly other
organs. Up to a certain degree of damage, even the sole, transi-
ent inhibition of endogenous BMP-9 activity might suffice to
allow for better liver regeneration and healing.
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